Volastra in-licenses Amgen's KIF18A inhibitor sovilnesib
Volastra Therapeutics has concluded the in-licensing of Amgen’s oral, first-in-class small molecule KIF18A inhibitor, sovilnesib (AMG650).
Stay updated with breaking news from Scott Drutman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Volastra Therapeutics has concluded the in-licensing of Amgen’s oral, first-in-class small molecule KIF18A inhibitor, sovilnesib (AMG650).
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!